非肌层浸润性膀胱癌预后相关分子标志物的研究进展被引量：4

下载PDF

导出

摘要膀胱癌是我国最常见的泌尿系肿瘤之一，在初次诊断的患者中约75％是非肌层浸润性膀胱癌（NMIBC）［1］。目前以临床病理因素为基础的EORTC评分系统［2］被广泛用于判断西方国家NMI-BC的复发及进展风险。但是EORTC评分系统并不能完全反映NMIBC的高度异质性。

作者张姣王海涛

机构地区天津医科大学肿瘤医院

出处《山东医药》 CAS 2014年第39期89-91,共3页 Shandong Medical Journal

基金国家自然科学基金项目(81071787) 天津市应用基础及前沿技术研究计划项目(08JCYBJC05300)

关键词膀胱肿瘤非肌层浸润性膀胱癌肿瘤复发肿瘤进展

分类号 R730.7 [医药卫生—肿瘤]

引文网络
相关文献

参考文献23

1Zlotta AR, Roumeguere T, Kuk C, et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer [ J ]. Eur Urol, 2011,59(6) :1026-1031.
2Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predic- ting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trims[ J]. Eur Urol, 2006 ,g9 (3) :466-475.
3van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade ( FGFR3/MIB-1 ) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer[ J]. Eur Uml, 2010,58 ( 3 ) : 433-441.
4van Rhijn BW, Liu L, Vis AN, et al. Prognostic value of molecu- lar markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer [J]. BJUInt, 2012,110(8) :1169-1176.
5Neuzillet Y, Paoletti X, Ouerhani S, et al. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer [ J ]. PLoS ONE, 2012,7 (12) :e48993.
6George B, Datar RH, Wu L, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder caneer[J]. J Clin Oneol, 2007,25 (34) :5352-5358.
7Oh JJ, Ji' SH, Choi DK, et al. A six-week course of bacillus Calmette-Gu6rin prophylaxis is insufficient to prevent tumor recur- rence in nonmuscle invasive bladder cancer with strong-positive ex- pression of p53[J]. Ontology, 2010,79(545):440-446.
8Mitra AP, Hansel DE, Cote RJ. Prognostic value of cell-cycle reg-ulation biomarkers in bladder cancer[ J ]. Semin Oncol, 2012,39 (5) :524-533.
9Burger M, van der Aa MN, van Oers JM, et al. Prediction of pro- gression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study [J]. Eur Urol, 2008,54(4) :835-843.
10Zuivedoon TC, van der Aa MN, van der Kwast TH, et al. Fibro- blast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer[ J]. Clin Cancer Res, 2010,16 ( 11 ) :3011-3018.